Home/ Stocks/ KOD

Kodiak Sciences Inc Common Stock

KOD XNAS

$99.30 +11.28 (+12.39%) ▲ 15-min delayed

Open

$92.83

High

$100.17

Low

$91.00

Volume

1.05M

Market Cap

$6.24B

About Kodiak Sciences Inc Common Stock

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 124 Website →

Related Market News

No specific coverage for KOD yet. Check out our latest market news or earnings calendar.

Get KOD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Kodiak Sciences Inc Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.